Abstract: Novel anti-CD25 antibodies and antigen-bind fragments thereof that do not inhibit the binding of interleukin-2 (IL-2) to CD25, and the use thereof for treating cancer or an infectious disease. Also, fusion proteins including the antibodies and antigen-bind fragments, nucleic acids encoding the antibodies and antigen-bind fragments, and an expression vectors including the nucleic acids. Further, pharmaceutical compositions including the fusion proteins or the antibodies and antigen-bind fragments.

Abstract: The present invention relates to a compound of the following formula (I): The invention also relates to uses thereof as dye or pigment, notably as a luster pigment. The invention relates also to a reflective or photonic or nanophotonic or optoelectronic device comprising a compound of the invention. The invention relates also to a metal-like reflective coating, a metal-like particle or an organic-based metal-like liquid film comprising a compound of the invention.

Abstract: The present invention relates to a compound of formula (I): wherein P1, P3, P4 and P5 are amino acid residues or amino acid like structures. The invention also relates to a compound of formula (I) for its use as a Caspase-2 inhibitor and for its therapeutical use. It also concerns the use of a compound of formula (I) as activity base probe to selectively detect Caspase-2 activity.

Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.

Abstract: The present invention relates to an atomic force microscope for evaluating a surface of a sample, comprising a sample holder, having a first zone suitable for receiving the sample mounted in a stationary manner, a probe having a tip able to be positioned facing the surface of the sample, the microscope being configured to allow an adjustment of a position of the tip relative to the surface, and a support, the sample holder having at least one second zone, separate from the first zone and stationary relative to the support, the sample holder being deformable so as to allow a relative movement of the first zone with respect to the second zone, and the microscope comprising a detector able to detect a movement of the first zone relative to the second zone.

Abstract: The present invention relates to methods for predicting the survival time of patients suffering from a lung cancer.

Abstract: The present invention relates to improved clot retrieval devices, wherein at least the part of the device intended to be in contact with a clot is coated with at least one chromatin binding agent selected from the group consisting of digoxigenin, a digoxigenin derivative, distamycin and a distamycin derivative. The present invention also relates to a method of producing said improved clot retrieval device. The present invention also relates to a method of prevention and/or treatment of stroke in a subject, comprising removing at least one clot using the clot retrieval device coated with said least one chromatin binding agent.

Abstract: A calibration standard for determining an intensity decay related to an evanescent field generated close to the interface between a sample to be tested and a substrate on which the sample is to be deposited, preparation and analysis methods and use thereof.

Abstract: A fluidic system for loading a therapeutic or imaging agent into the lumen of extracellular vesicles from producer cells, including at least one container, a liquid medium contained in the container, producer cells, a liquid medium stirrer and a device for controlling the speed of the stirrer suitable for the growth of the producer cells, wherein it also includes a device for controlling the speed of the stirrer and the stirrer, of which the shape and dimensions of the container are suitable for generating a turbulent flow of the liquid medium in the container for exerting shear stresses on the producer cells in order to carry out the loading of a therapeutic or imaging agent into the lumen of the extracellular vesicles produced simultaneously by the fluidic system.

Abstract: The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they have further been found to inhibit the production of inflammatory cytokines in immune cells, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of an inflammatory disorder, an autoimmune disorder, an autoinflammatory disorder, or an interferonopathy, such as, e.g., lupus erythematosus, dermatomyositis or rheumatoid arthritis.

Abstract: The invention relates to a method of predicting therapeutic responses to TNF blockers before anti-TNF therapy comprising analyzing immune parameters to selected stimuli in patients before therapy and its use for anti-TNF therapy. The invention relates also to a method of determining a predictive biomarker of response to anti-TNF therapy and to the use of the predictive biomarker obtained by the method.

Abstract: A fluidic system for producing extracellular vesicles from suspended producer cells, including at least one container, a liquid medium contained in the container, suspended producer cells, a liquid medium agitator, a device for controlling the speed of the agitator suitable for the growth of the suspended producer cells, wherein the device for controlling the speed of the agitator, the agitator and the shape and dimensions of the container are suitable for generating a turbulent flow of the liquid medium in the container for exerting shear stresses on the producer cells in order to carry out the production of extracellular vesicles, the Kolmogorov length of the flow being less than or equal to 50 ?m.

Abstract: The present invention relates to an inductive dipole element for a superconducting microwave quantum circuit. The dipole element comprises a DC-SQUID formed by a pair of Josephson junctions shunted by an inductance, wherein the Josephson junctions have equal energy, and the Josephson junctions and the inductance are arranged such that each of the junctions forms a loop with the inductance. The two loops are asymmetrically threaded with external magnetic DC fluxes ?ext1 and ?ext2, respectively, such that ?ext1=? and ?ext2=0, wherein parametric pumping is enabled by modulating the total flux ??=?ext,1+?ext,2 threading the dipole element, thereby allowing even-wave mixing between modes that participate in the dipole element with no Kerr-like interactions.

Abstract: The present invention relates to antibodies against the endothelin receptor subtype A, in particular monoclonal antibodies, fragments or derivatives thereof. The present invention also relates to the therapeutic or diagnostic use of this antibody or as a research tool in the field of cancers, in particular glioblastoma.

Abstract: The present invention relates to the use of a cyclic peptide comprising the tripeptide reproducing a binding site of fertilin beta to the oocyte integrin, for improving cellular energy metabolism. More particularly, the invention concerns the use of a cyclic peptide comprising the tripeptide FEEc for stimulating the energy metabolism of gametes or embryonic cells in the context of medically assisted procreation (MAP) protocols, in particular promoting the in vitro maturation of the oocyte, the fertilization rate and the birth rate.

Abstract: An organic electrochemical device including a substrate on which a source and drain are located, a gate electrode, and either a conductive channel of at least one organic conductive track or a conductive channel including at least one organic conductive track. Also, a method of manufacturing the organic electrochemical device.

Abstract: The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an immunomodulatory antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and a polypeptide comprising the amino acid sequence of the sushi domain of the IL-15R? or derivatives thereof; and uses thereof.

Abstract: A device for analyzing the regularity and symmetry of a sequence of N gait or running cycles of a person, comprising sensors for measuring raw time signals of a physical movement variable of a body segment, a processing unit connected to the sensors for measuring and configured to separate the raw time signals into distinct time signals Ci, the Ci series being associated with a given gait or running cycle i of the person, to calculate at least one similarity coefficient between the signal Ci associated with gait or running cycle i and another signal Cj associated with a gait or running cycle j of the person. A display is configured to display the matrix M(i,j) with each value of the similarity coefficient shown in the matrix M(i,j) in color to form a graduated color scale indicating the similarity between the gait or running cycles i and j.

Abstract: The invention relates to a method of predicting therapeutic responses to TNF blockers before anti-TNF therapy comprising analyzing immune parameters to selected stimuli in patients before therapy and its use for anti-TNF therapy. The invention relates also to a method of determining a predictive biomarker of response to anti-TNF therapy and to the use of the predictive biomarker obtained by the method.

Abstract: A method for quantifying the balance of an individual includes segmenting, as a function of time, a statokinesigram(s) of an individual so as to generate several statokinesigram portions; extracting, from the statokinesigram portions, values of at least one trajectory parameter; determining the value of at least two quantifiers, from the values of trajectory parameters extracted in the extraction step, for each of the statokinesigram portions generated in the segmentation step; and determining said value representative of the balance of the individual from the values of the quantifiers of each of the statokinesigram portions. The method may be implemented by a processor and memory.